First Tracks Biotherapeutics Inc (TRAX)

$15.96 +0.14 (0.88%)
Market Cap 556.88M
Revenue (ttm) 0.00
Net Income (ttm) -163.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 471,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 34.89M
Stochastic %K 24%
Beta N/A
Analysts Strong Sell
Price Target $39.28
Latest News on TRAX
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

May 21, 2026, 4:15 PM EDT - 10 days ago

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:15 PM EDT - 17 days ago

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

2026-05-08T22:52:09.000Z - 23 days ago

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

2026-05-04T08:40:30.000Z - 27 days ago

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

2026-04-28T10:10:15.000Z - 4 weeks ago

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

First Tracks Biotherapeutics initiated with an Outperform at Leerink

2026-04-24T11:36:50.000Z - 5 weeks ago

First Tracks Biotherapeutics initiated with an Outperform at Leerink

ANAB

First Tracks Biotherapeutics initiated with an Overweight at Barclays

2026-04-23T12:11:58.000Z - 5 weeks ago

First Tracks Biotherapeutics initiated with an Overweight at Barclays

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

2026-04-23T12:11:27.000Z - 5 weeks ago

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

Apr 20, 2026, 9:15 AM EDT - 5 weeks ago

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases